ASSESSMENT OF THE POTENTIAL AMELIORATING EFFECTS OF BM-MSCSOR INSULIN ON THE ALTERED METABOLIC STATUS OF PANCREAS, LIVER AND KIDNEYIN STZ-DIABETIC RATS.

The current study was designed to investigate the probable hypoglycemic, hypolipidemic and hepato-renal protective effects of bone marrow derived mesenchymal stem cells (BM-MSCs) in comparison with insulin treatment in diabetic rats. Animals were classified into 4 groups; control group, diabetic group (D) received a single IP STZ dose (45 mg/kg b.w), D + insulin (0.75 IU/100 gm bw,SC daily for 4 weeks) group and D + BM-MSCs (single IV dose of 106 cell/rat). Herein, both insulin and BM-MSCs administration significantly improved the hyperglycemic status resulting from diabetes induction, as evidenced by lowered blood glucose, HbA1c and AGEs levels, while enhanced serum insulin, C-peptide and HO-1 levels, compared to the diabetic group. Regarding lipid metabolism, the increased levels of lipid fractions (TL, TG, TC and LDL-C) and the reduced HDL-C level in diabetic rats were reverted back to near normal values as a consequence to BM-MSCs treatment; indicating further, its hypolipidemic effect; in addition to enhancing the protein metabolism in diabetic rats. Furthermore, BM-MSCs was found to has hepato-renal protective effects via improving liver functions in diabetic rats; confirmed by decreased serum AST, ALT, ALP and γ-GT activities associated with decreased total bilirubin but increased total protein and albumin levels; and improving kidney status; indicated by the decreased serum levels of creatinine, uric acid and urea; compared to the diabetic group. Current findings clearly point out the health benefits of BM-MSCs; more than insulin; in ameliorating various metabolic disorders and hepato-renal diabetic complications.